TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26654905
Drug: Iodine supplementation
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iodine supplementation (150 μg/d)
Study: 24054920
Drug: No occlusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: No occlusion and oral anticoagulation
Study: 14522569
Drug: Clopidogrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading dose 300 mg, followed by 75 mg daily) with pre-treatment of atorvastatin or simvastatin
Study: 14522569
Drug: Clopidogrel (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (loading dose 300 mg, followed by 75 mg daily)
Study: 10998024
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate nasal drops 400 microgram once daily
Study: 8641498
Drug: Determination of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determination of local antisperm antibodies (Ab) with the mixed antiglobulin reaction (MAR) immunoglobulin (Ig) G and IgA
Study: 6085376
Drug: Nitrendipine (NTP)
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (NTP) 5 mg b.i.d. (increased to 20 mg b.i.d. as needed) + Hydrochlorothiazide (HCTZ) 25 mg daily
Study: 6085376
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) b.i.d. + Hydrochlorothiazide (HCTZ) 25 mg daily
Study: 29579168
Drug: Apixaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apixaban (5 mg b.i.d.)
Study: 29579168
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonists (VKA, INR 2-3)
Study: 9203648
Drug: Hyperimmune anti-HIV
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune anti-HIV intravenous immunoglobulin (HIVIG) 200 mg/kg
Study: 9203648
Drug: Hyperimmune anti-HIV
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperimmune anti-HIV intravenous immunoglobulin (HIVIG)
Study: 3680599
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg sustained release (SR) preparation
Study: 3680599
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg tid dosing regimen
Study: 3680599
Drug: SR PPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR PPA 75 mg
Study: 27542302
Drug: Adalimumab (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab (loading dose 80 mg; biweekly dose 40 mg)
Study: 26386802
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg intravenous enoxaparin
Study: 23885702
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day high‐oleic sunflower ethyl ester oil softgel capsules + foods containing 7 g/day stearidonic acid soybean oil
Study: 23885702
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day EPA oil ethyl ester softgel capsules + foods containing 7 g/day high‐oleic sunflower oil
Study: 23885702
Drug: 1.5 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/day high‐oleic sunflower ethyl ester oil softgel capsules + foods containing 7 g/day high‐oleic sunflower oil
Study: 20578930
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg MPH
Study: 10203935
Drug: Nicotine cigarette
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine cigarette (.7‐mg estimated nicotine delivery)
Study: 10203935
Drug: Placebo cigarette
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cigarette (.05‐mg nicotine delivery)
Study: 29466961
Drug: Whole brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole brain radiation therapy (WBRT)
Study: 29453872
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (treatment by primary medicine team)
Study: 26917504
Drug: RCT-18 (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-18 (180 mg, once or twice weekly)
Study: 26917504
Drug: RCT-18 (360
Approvals — FDA: no, EMA: no, PMDA: no
Description: RCT-18 (360 mg, weekly)
Study: 16633117
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment group (ATG) with ofloxacin or levofloxacin (single dose or BID for 5 days)
Study: 16633117
Drug: Supportive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive treatment only group (STG)
Study: 16633117
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment group (ATG)
Study: 12660335
Drug: Diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 120 mg/d
Study: 12660335
Drug: Diltiazem 180
Normalized name: diltiazem 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 180 mg/d
Study: 12660335
Drug: Diltiazem 240
Normalized name: diltiazem 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem 240 mg/d
Study: 7071529
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine (subcutaneous injection)
Study: 7071529
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (subcutaneous injection)
Study: 7071529
Drug: Pneumococcal vaccine
Normalized name: PNEUMOCOCCAL VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal vaccine (intramuscular injection)
Study: 3908116
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg AG/day
Study: 3908116
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g AG/day
Study: 29596644
Drug: Compound-level intervention
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound-level intervention (chlorinated drinking water, upgraded sanitation, and handwashing promotion)
Study: 24963025
Drug: Low-dose S-IFE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose S-IFE (1 g/kg/d)
Study: 24963025
Drug: Control dose
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control dose S-IFE (approximately 3 g/kg/d)
Study: 24963025
Drug: Low-dose S-IFE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose S-IFE
Study: 24963025
Drug: Low-dose S-IFE
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose S-IFE and Control dose S-IFE
Study: 16052544
Drug: Fast-releasing ER
Normalized name: phentermine hydrochloride Extended Release Oral Tablet [Pro-Fast]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-releasing ER formulation
Study: 16052544
Drug: Medium-releasing ER
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-releasing ER formulation
Study: 16052544
Drug: Slow-releasing ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-releasing ER formulation
Study: 16052544
Drug: Slightly-fast-releasing ER
Normalized name: phentermine hydrochloride Extended Release Oral Tablet [Pro-Fast]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slightly-fast-releasing ER formulation
Study: 16052544
Drug: Slightly-slow-releasing ER
Normalized name: ferrous sulfate Extended Release Oral Tablet [Slow-Fe]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slightly-slow-releasing ER formulation
Study: 16052544
Drug: 12-h IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-h IV infusion of valproic acid (reference)
Study: 12459665
Drug: IDD-D Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDD-D Propofol (2.5 mg/kg bolus + 0.2 mg/kg/min infusion for 30 min)
Study: 12459665
Drug: IDD-D Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IDD-D Propofol (30-min infusion)
Study: 7589025
Drug: Fatty cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty cream 0.1% mometasone furoate (EFC)
Study: 7589025
Drug: Fatty cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatty cream 0.1% hydrocortisone‐17‐butyrate (LLFC)
Study: 7004827
Drug: Fenclofenac (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenclofenac (900 mg daily)
Study: 7004827
Drug: Indometacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indometacin (100 mg daily)
Study: 28634002
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + acupressure (AP group)
Study: 28634002
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment + mock acupressure (mock AP group)
Study: 20662907
Drug: Initial periodontal
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial periodontal treatment
Study: 20662907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no initial periodontal treatment)
Study: 16004813
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with surgery (36 patients)
Study: 16004813
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with surgery
Study: 10677808
Drug: Hydrocolloid patches
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid patches containing TACA (triamcinolone acetonide)
Study: 10677808
Drug: Hydrocolloid patches
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid patches containing TACA
Study: 22983593
Drug: Atropine 10
Normalized name: Isopto Atropine 10 MG/ML Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 10 μg/kg
Study: 21429067
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal gel (1 mg/2 mg)
Study: 21429067
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal tablets (3 mg)
Study: 16944044
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy for 24 months
Study: 12738139
Drug: Metronidazole (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (250 mg orally three times per day) and erythromycin (250 mg orally four times per day) for 10 days
Study: 12738139
Drug: Placebo pills
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills for 10 days
Study: 9071898
Drug: Multimodal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal therapy (pre‐operative chemotherapy, Patey mastectomy, flap irradiation and adjuvant hormone therapy)
Study: 8416161
Drug: Tolrestat (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolrestat (200 mg/d given in the morning)
Study: 21135170
Drug: Oral glucocorticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glucocorticosteroids (GCSs)
Study: 21135170
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of anti-TGF-β and anti-IL-10 Abs
Study: 18973494
Drug: Early losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early losartan therapy
Study: 18973494
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no losartan therapy)
Study: 17165637
Drug: ezetimibe/simvastatin, 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin, 10/20 mg/d
Study: 17165637
Drug: ezetimibe/simvastatin, 10/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ezetimibe/simvastatin, 10/40 mg/d
Study: 7761882
Drug: loratadine 10mg
Normalized name: LORATADINE 10MG TAB
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: loratadine 10mg daily
Study: 7761882
Drug: astemizole 10mg
Normalized name: ASTEMIZOLE 10MG TAB
DrugBank: Astemizole (DB00637)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: astemizole 10mg daily
Study: 3287943
Drug: SCH 33861
Normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH 33861 (topical angiotensin converting enzyme inhibitor)
Study: 19738134
Drug: Accelerated infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Accelerated infusion of streptokinase
Study: 19738134
Drug: Conventional infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional infusion of streptokinase
Study: 23316063
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM N(G)-nitro-l-arginine methyl ester (l-NAME; NO synthase inhibitor)
Study: 23316063
Drug: 10 mM
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM ketorolac (COX inhibitor)
Study: 23316063
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of l-NAME + ketorolac
Study: 21077801
Drug: Low-dose prednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose prednisolone (5-7.5 mg) for at least 2 years (P-group)
Study: 21077801
Drug: No prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No prednisolone treatment (NoP-group)
Study: 19808874
Drug: Ipilimumab at
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab at 3 mg/kg and then monthly at 1 mg/kg x 3 months (dose level 1), escalating to 3 mg/kg monthly x 4 months (dose level 2)
Study: 16739319
Drug: Intraarterial ACNU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarterial ACNU administration (17 patients)
Study: 16739319
Drug: Intravenous ACNU
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ACNU administration (16 patients)
Study: 14715359
Drug: High-dose nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose nitroglycerin
Study: 7798535
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate 500 micrograms twice a day
Study: 3277875
Drug: Prostaglandin E2
Normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Prostaglandin E2 vaginal suppositories (2.5 mg PGE2 in Witepsol S55)
Study: 3277875
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin gel (1 mg PGE2 in 5 g hydroxypropylmethyl cellulose)
Study: 3277875
Drug: Intracervical prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical prostaglandin gel
Study: 29678471
Drug: Radium-223 (Ra-223)
Normalized name: Radium Ra-223
DrugBank: Radium Ra-223 (DB12813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 (Ra-223) therapy
Study: 11014375
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy in chronic aortic regurgitation (AR)
Study: 11014375
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy in chronic mitral regurgitation (MR)
Study: 11014375
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy in mitral valve prolapse or hypertrophic cardiomyopathy
Study: 11014375
Drug: Vasodilator therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasodilator therapy in other primary causes of MR
Study: 30702758
Drug: Culturally adapted
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally adapted guided internet‐based cognitive behavior therapy (ICBT) for 8 weeks
Study: 30446003
Drug: Screening trial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening trial prior to SCS implant
Study: 26415549
Drug: Temoporfin photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temoporfin photodynamic therapy (PDT) plus chemotherapy and stent
Study: 26415549
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and stent without temoporfin PDT
Study: 15295370
Drug: Foley catheter
Normalized name: Bard Foley Catheter 18FR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foley catheter with extra-amniotic saline infusion (EASI)
Study: 29930229
Drug: Mindfulness-Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Stress Reduction (MBSR) therapy
Study: 20959284
Drug: Titrated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oxygen treatment
Study: 20959284
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow oxygen treatment
Study: 18238963
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive (0.75 mg ethinyl estradiol and 6 mg norelgestromin)
Study: 18238963
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (35 mcg ethinyl estradiol and 250 mcg norgestimate)
Study: 18238963
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive
Study: 16792583
Drug: drugs +
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: drugs + placebo
Study: 14624409
Drug: alpha-blockade (prazosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha-blockade (prazosin 3 mg/d)
Study: 11053072
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg twice daily orally for three months
Study: 8932352
Drug: Early alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early alternating chemotherapy
Study: 8932352
Drug: Late alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late alternating chemotherapy
Study: 1434266
Drug: Adjuvant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant combination chemotherapy including cis‐platinum
Study: 1434266
Drug: Adjuvant combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant combination chemotherapy including cis‐platinum with 3 or more cycles
Study: 1434266
Drug: Pre‐operative treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐operative treatment such as irradiation and intra‐arterial chemotherapy
Study: 12269263
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (general)
Study: 3904322
Drug: Metoprolol-hydralazine treatment
Normalized name: hydralazine / hydrochlorothiazide / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol-hydralazine treatment
Study: 29277158
Drug: Symbiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic treatment (Lactobacillus paracasei, L. rhamnosus, L. acidophilus, Bifidobacterium lactis plus 6 g of fructo‐oligosaccharides)
Study: 29277158
Drug: Control (placebo:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo: 6 g of maltodextrin)
Study: 29277158
Drug: Symbiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic treatment
Study: 26038091
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg intravenous rontalizumab every 4 weeks
Study: 26038091
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg subcutaneous rontalizumab every 2 weeks
Study: 24190613
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sildenafil per day for 12 weeks
Study: 22894176
Drug: Migraine Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Migraine Group (MG)
Study: 20571436
Drug: Extra methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra methadone (50% extra dose on top of prescribed daily dosage)
Study: 16380486
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion (LIP) with plasma FFA approximately 1,034 micromol/l
Study: 16380486
Drug: Lipid infusion
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion (LIP)
Study: 16380486
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) without lipid infusion
Study: 12760698
Drug: Dyract Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyract Flow (Dentsply DeTrey) with acid etching and/or bonding agent
Study: 10790815
Drug: 0.05% tretinoin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% tretinoin cream (Retinova)
Study: 1429786
Drug: Marshall‐MacIntosh technique
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marshall‐MacIntosh technique with Kennedy ligament‐augmentation device
Study: 3841005
Drug: BRL 20627
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRL 20627 (10 mg i.v.)
Study: 3841005
Drug: Zetidoline (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zetidoline (20 mg orally)
Study: 3841005
Drug: BK 34/530
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK 34/530 (50 mg orally)
Study: 3841005
Drug: BK 34/530
Approvals — FDA: no, EMA: no, PMDA: no
Description: BK 34/530 (100 mg orally)
Study: 30585498
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy (f‐ESWT)
Study: 25790903
Drug: Symptoms of
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptoms of psychopathology, experience with tablet technology, or difficulties operating the device